BR112014001855A2 - construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto - Google Patents
construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construtoInfo
- Publication number
- BR112014001855A2 BR112014001855A2 BR112014001855A BR112014001855A BR112014001855A2 BR 112014001855 A2 BR112014001855 A2 BR 112014001855A2 BR 112014001855 A BR112014001855 A BR 112014001855A BR 112014001855 A BR112014001855 A BR 112014001855A BR 112014001855 A2 BR112014001855 A2 BR 112014001855A2
- Authority
- BR
- Brazil
- Prior art keywords
- construct
- dimer
- antigen
- protein
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512138P | 2011-07-27 | 2011-07-27 | |
PCT/EP2012/064632 WO2013014208A2 (en) | 2011-07-27 | 2012-07-25 | Antigen binding constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014001855A2 true BR112014001855A2 (pt) | 2017-02-21 |
Family
ID=46579044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014001855A BR112014001855A2 (pt) | 2011-07-27 | 2012-07-25 | construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto |
Country Status (18)
Country | Link |
---|---|
US (2) | US9499612B2 (pt) |
EP (1) | EP2736925A2 (pt) |
JP (1) | JP5987057B2 (pt) |
KR (1) | KR101632620B1 (pt) |
CN (1) | CN103842380A (pt) |
AU (1) | AU2012288846B2 (pt) |
BR (1) | BR112014001855A2 (pt) |
CA (1) | CA2842099A1 (pt) |
CL (1) | CL2014000204A1 (pt) |
CO (1) | CO7020847A2 (pt) |
CR (1) | CR20140047A (pt) |
DO (1) | DOP2014000017A (pt) |
EA (1) | EA028886B1 (pt) |
HK (1) | HK1198446A1 (pt) |
MA (1) | MA35352B1 (pt) |
MX (1) | MX2014001019A (pt) |
PE (1) | PE20141659A1 (pt) |
WO (1) | WO2013014208A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
MX2013005847A (es) * | 2010-11-24 | 2013-12-12 | Glaxo Group Ltd | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. |
KR102240318B1 (ko) | 2011-06-23 | 2021-04-15 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
TW201643179A (zh) | 2015-03-11 | 2016-12-16 | 葛蘭素史克智慧財產發展有限公司 | Tslp結合蛋白 |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
EP3429624A4 (en) * | 2016-03-16 | 2020-04-22 | The Regents of The University of California | PROTEIN A BINDING POLYPEPTIDES, ANTI-EPHA2 ANTIBODIES AND METHODS OF USE THEREOF |
AU2017247796A1 (en) | 2016-04-05 | 2018-09-27 | Glaxosmithkline Intellectual Property Development Limited | Inhibition of TGFBeta in immunotherapy |
JP2020514301A (ja) * | 2017-01-06 | 2020-05-21 | モメンタ ファーマシューティカルズ インコーポレイテッド | 改変されたFc抗原結合ドメイン構築体に関する組成物および方法 |
CN109021103B (zh) * | 2017-06-12 | 2022-08-23 | 上海睿智化学研究有限公司 | 抗人血管内皮生长因子的抗体及其制备方法和应用 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
JP2023517345A (ja) | 2020-03-13 | 2023-04-25 | ジェネンテック, インコーポレイテッド | 抗インターロイキン-33抗体及びその使用 |
WO2022175481A1 (en) * | 2021-02-19 | 2022-08-25 | Dotbio Pte. Ltd. | Vegfa-binding molecules |
WO2023014892A1 (en) * | 2021-08-04 | 2023-02-09 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
AU2022327397A1 (en) * | 2021-08-13 | 2024-03-14 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-vegf a and -vegf c bispecific antibody and use thereof |
KR20240019034A (ko) * | 2022-08-02 | 2024-02-14 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
WO2024055995A1 (zh) * | 2022-09-14 | 2024-03-21 | 寻济生物科技(北京)有限公司 | 一种抗vegfa融合蛋白及其制备方法和应用 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
AU758240B2 (en) | 1998-02-25 | 2003-03-20 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
DK1078051T3 (da) | 1998-05-13 | 2008-04-07 | Domantis Ltd | Fagvisningsselektionssystem til selektion af korrekt foldede proteiner |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
GB2375112A (en) | 2000-02-03 | 2002-11-06 | Domantis Ltd | Combinatorial protein domains |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
CN101039959A (zh) * | 2004-06-30 | 2007-09-19 | 杜门蒂斯有限公司 | 用于治疗炎性疾病的组合物和方法 |
EP1776385A1 (en) | 2004-07-21 | 2007-04-25 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
ZA200702427B (en) * | 2004-09-17 | 2008-12-31 | Domantis Ltd | Compositions monovalent for CD40L binding and methods of use |
EP1921090B1 (en) | 2005-07-22 | 2015-01-14 | Kyowa Hakko Kirin Co., Ltd. | Genetically modified antibody composition |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
WO2008143954A2 (en) * | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
CN102131827A (zh) * | 2007-12-13 | 2011-07-20 | 葛兰素集团有限公司 | 用于肺部传递给药的组合物 |
JP6157046B2 (ja) * | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
EP2401298A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
BRPI1013807A2 (pt) * | 2009-05-28 | 2019-09-24 | Glaxo Group Ltd | composição, uso de uma composição, antagonista, sequência de polinucleotídeo, célula hospedeira recombinante transformada ou transfectada, método para a produção de uma composição, método para prevenir ou tratar um paciente, molécula de ligação de antígeno de marcação dual, e, proteína de ligação de antígeno. |
US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
WO2011063348A1 (en) * | 2009-11-23 | 2011-05-26 | Amgen Inc. | Monomeric antibody fc |
MX2013005847A (es) * | 2010-11-24 | 2013-12-12 | Glaxo Group Ltd | Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf. |
EP2670778A1 (en) * | 2011-02-02 | 2013-12-11 | Glaxo Group Limited | Novel antigen binding proteins |
-
2012
- 2012-07-25 US US14/235,330 patent/US9499612B2/en not_active Expired - Fee Related
- 2012-07-25 CA CA2842099A patent/CA2842099A1/en not_active Abandoned
- 2012-07-25 WO PCT/EP2012/064632 patent/WO2013014208A2/en active Application Filing
- 2012-07-25 PE PE2014000126A patent/PE20141659A1/es not_active Application Discontinuation
- 2012-07-25 JP JP2014522089A patent/JP5987057B2/ja not_active Expired - Fee Related
- 2012-07-25 KR KR1020147005082A patent/KR101632620B1/ko active IP Right Grant
- 2012-07-25 EA EA201391812A patent/EA028886B1/ru not_active IP Right Cessation
- 2012-07-25 EP EP12738476.6A patent/EP2736925A2/en not_active Ceased
- 2012-07-25 BR BR112014001855A patent/BR112014001855A2/pt not_active IP Right Cessation
- 2012-07-25 MX MX2014001019A patent/MX2014001019A/es unknown
- 2012-07-25 AU AU2012288846A patent/AU2012288846B2/en not_active Ceased
- 2012-07-25 CN CN201280047197.3A patent/CN103842380A/zh active Pending
-
2014
- 2014-01-27 CL CL2014000204A patent/CL2014000204A1/es unknown
- 2014-01-27 DO DO2014000017A patent/DOP2014000017A/es unknown
- 2014-01-28 CR CR20140047A patent/CR20140047A/es unknown
- 2014-01-29 CO CO14018316A patent/CO7020847A2/es unknown
- 2014-02-18 MA MA36759A patent/MA35352B1/fr unknown
- 2014-11-26 HK HK14111941.1A patent/HK1198446A1/xx unknown
-
2016
- 2016-10-14 US US15/294,058 patent/US20170029494A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2013014208A2 (en) | 2013-01-31 |
EA028886B1 (ru) | 2018-01-31 |
MX2014001019A (es) | 2014-05-13 |
CN103842380A (zh) | 2014-06-04 |
EA201391812A1 (ru) | 2014-06-30 |
AU2012288846A1 (en) | 2014-02-06 |
US20140205604A1 (en) | 2014-07-24 |
US9499612B2 (en) | 2016-11-22 |
PE20141659A1 (es) | 2014-11-21 |
CL2014000204A1 (es) | 2014-07-25 |
KR20140041908A (ko) | 2014-04-04 |
HK1198446A1 (en) | 2015-04-24 |
CR20140047A (es) | 2014-03-24 |
DOP2014000017A (es) | 2014-04-30 |
EP2736925A2 (en) | 2014-06-04 |
CO7020847A2 (es) | 2014-08-11 |
JP5987057B2 (ja) | 2016-09-06 |
AU2012288846B2 (en) | 2016-05-19 |
JP2014523746A (ja) | 2014-09-18 |
KR101632620B1 (ko) | 2016-06-23 |
MA35352B1 (fr) | 2014-08-01 |
CA2842099A1 (en) | 2013-01-31 |
US20170029494A1 (en) | 2017-02-02 |
WO2013014208A3 (en) | 2013-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001855A2 (pt) | construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto | |
IL267225B (en) | Bispecific igg4 antibodies are asymmetrically sequenced | |
BR112015002085A2 (pt) | proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
BR112013023653A2 (pt) | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica | |
BR112014011137A2 (pt) | polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento | |
DK3912642T3 (da) | Modificeret antistof, antistofkonjugat og fremgangsmåde til fremstilling deraf | |
BR112015007120A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo | |
BR112014007587A2 (pt) | cápsula para preparar uma bebida, sistema para preparar bebida e processo para preparar uma bebida | |
BR112013031916A2 (pt) | composição nucicional,uso de uma composição nutricional, processo para a fabricação de uma composição nutricional, e produto | |
BR112013033811A2 (pt) | composição, método de preparação da composição, e, composto | |
DK2831241T3 (da) | Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression. | |
BR112015013188A2 (pt) | método de fermentação otimizado | |
BR112015004487A2 (pt) | método limpo para preparar d, l-metionina | |
CL2015000174A1 (es) | Método y aparato de fermentación de mosto para la produccion de vino. | |
ES2974687T3 (es) | Métodos para la fabricación de polipéptidos procesados proteolíticamente | |
BR112013030423A2 (pt) | método para produção de biocoque | |
DK2768875T3 (da) | Aminoplast-tværbinderresin-sammensætninger, proces til fremstilling deraf og fremgangsmåde til anvendelse | |
DK2787982T3 (da) | Sammensætning til tarmpræparat | |
BR112014004789A2 (pt) | extrusor de laboratório e método para produzir produtos farmacêuticos | |
CO6842021A2 (es) | Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos | |
BR112013021775A2 (pt) | bactéria corineforme, e, método para produzir um l-aminoácido | |
BR112013022306A2 (pt) | método, e, composição | |
BR112014023401A2 (pt) | método para produzir batoque de perfuração-laminação | |
BR112014014285A2 (pt) | composição, e, método para fabricar uma composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |